Pleural cavity

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Multimedia, Mesothelioma, Malignancy, Research, Disease, Patient, Lung, SOC, Pleural cavity, MPE, RSO, Drainage, Malignant pleural effusion, Cancer, Pharmaceutical industry

The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.

Key Points: 
  • The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.
  • (Photo: Dan Ryan)
    Malignant pleural effusion (MPE) is the build up of fluid in the lining membrane (pleura) of the lungs.
  • RSO’s novel, investigational anti-cancer treatment, RSO-021, is administered weekly directly into the pleural space following MPE drainage via an indwelling pleural catheter.
  • “Commencing the Phase 2 portion of our trial presents a major milestone for patients and their caregivers.”

The Lung Center at Mercy Introduces Interventional Pulmonology

Retrieved on: 
Wednesday, January 3, 2024
Magnet, Weinberg Center, Neuromuscular disease, Body cavity, Multimedia, Division, Sister, Elective surgery, Respiratory disease, Sleep, COPD, The Sisters of Mercy, Lung cancer, Disease, Interventional pulmonology, Pulmonology, Pleural cavity, Cancer, Sarcoidosis, Health, Asthma, Glen Burnie, Maryland, IP, Patient, Mercy Hospital, Diagnosis, Radiation, Nursing

BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP), Albert J. Polito, M.D., Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced. The expansion will essentially double the size of Mercy's current Lung Center with greater access for pulmonary patients.

Key Points: 
  • Interventional Pulmonology (IP) at Mercy Provides Minimally Invasive Procedures to Diagnose & Treat Lung Disease, Cancer / Mercy First in Maryland to Offer New Integrated Robotic Lung Navigational Technology
    BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP) , Albert J. Polito, M.D.
  • , Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced.
  • Beyond the downtown location, Mercy Lung Center staff see patients at the Overlea, Lutherville, Reisterstown, and Glen Burnie sites of Mercy Personal Physicians.
  • Founded in 1874 by The Sisters of Mercy, Mercy is home to the acclaimed Weinberg Center for Women's Health & Medicine and the $400+ million, 20-story Mary Catherine Bunting Center.

Pleural Dynamics Receives FDA 510(k) Clearance for its Novel ACES™ Automatic Continuous Effusion Shunt System

Retrieved on: 
Thursday, October 19, 2023
FDA, Health, Medical Devices, Pleurodesis, Critical Care Medicine (journal), Pleural cavity, Pleural effusion, Interventional radiology, Drainage, Abdomen, Patient, Food and Drug Administration, Food, Hospital, Medical device

Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.

Key Points: 
  • Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ACES™ Automatic Continuous Effusion Shunt System.
  • Pleural Dynamics’ patented ACES™ System addresses these shortcomings1 with its’ one-piece, fully implanted system that can be placed during a short hospital stay.
  • With this FDA 510(k) clearance, Pleural Dynamics will begin real-world clinical use of the ACES™ System with select hospitals and health systems.
  • Pleural Dynamics’ latest technology will play a vital role in improving the lives of patients with intractable pleural effusion.

BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis

Retrieved on: 
Thursday, October 12, 2023
Diagnosis, Health, Highland, Pleural disease, Cancer, Disease, Lung cancer, Collaboration, Malignancy, Pleural cavity, Innovation, DNA, University, Neoplasm, NHS Highland, Immunology, Public, NHS, University of the Highlands and Islands, Lung, Infection, Nucleic acid thermodynamics, UHI, Patient, Medical imaging, Genetics

Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.

Key Points: 
  • Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.
  • The study will involve a collaboration between BioCaptiva, University of the Highlands and Islands (UHI) and NHS Highland.
  • The occurrence of cfDNA in exudative pleural fluid samples is well established, but it is often present in insufficient concentrations for sequencing to confirm a cancer diagnosis (versus benign disease).
  • This route to diagnosis is particularly challenging for frail elderly patients and therefore improving the diagnostic utility of pleural fluid has both clinical and health economic benefits.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Abstract, Cleveland Clinic, Lung transplantation, Liquid biopsy, Lung, Pleural disease, Patient, Annual general meeting, American College of Chest Physicians, Sightline (architecture), Pleural cavity, American College, Medical imaging, Lung cancer

The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.

Key Points: 
  • The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.
  • Lung EpiCheck is being developed using markers discovered in Nucleix’s proprietary EpiCheck® Lung Atlas.
  • The Lung Atlas is an early lung cancer detection discovery platform that was constructed and developed as part of a multi-institutional effort to map epigenetic and genetic changes associated with early-stage lung cancer, focusing on stage I disease.
  • Session Title: Late-Breaking Development in Lung Cancer, Lung Transplantation, and Pleural Disease
    The CHEST 2023 abstracts will be available on the journal CHEST website at: https://journal.chestnet.org/meetings .

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Wednesday, September 13, 2023
Bispecific monoclonal antibody, Malignant pleural effusion, GMP, Antigen, YZY, International, Paracentesis, Epithelial cell adhesion molecule, CD3, CMC, Cancer, Ageing, Haemophilia, Pleural cavity, Stock exchange, CSPC, Peritoneum, Research, Immunotherapy, Shijiazhuang Pharma Group, MPE, Motherboard, Patient, Ophthalmology, SEHK, MA, TME, WIV, Immune system, Epitope, Tumor microenvironment, Ascites, Property management, Vaccine, Fine chemical, Pharmaceutical industry, PRC

The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.

Key Points: 
  • The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.
  • Since its establishment, YZY Biopharma focuses on the development of BsAbs in China.
  • In addition, the Company is also focusing on the development of the TME-targeted BsAbs, including Y101D and Y332.
  • Therefore, the execution of an appropriate CMC development strategy is vital to the success of the overall drug development program.

Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma

Retrieved on: 
Thursday, June 15, 2023
Mesothelioma, Pleural cavity, Orphan, Cancer, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Cell, Food, Pericardium, Pharmaceutical industry, Oil

and QUINCY, Mass., June 15, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the local administration of potent immune effector molecules to treat solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AVB-001 for the treatment of patients with mesothelioma.

Key Points: 
  • and QUINCY, Mass., June 15, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the local administration of potent immune effector molecules to treat solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AVB-001 for the treatment of patients with mesothelioma.
  • Pleural mesothelioma accounts for approximately 85% of new mesothelioma cases, followed by peritoneal mesothelioma (approximately 15%), and pericardium or tunica vaginalis mesothelioma (
  • In March 2023, Avenge received positive feedback from the FDA on its preclinical and clinical development plans for pleural malignant mesothelioma.
  • Avenge previously published preclinical data establishing the efficacy and safety of pleural administered AVB-001 for the treatment of pleural malignant mesothelioma.

New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors

Retrieved on: 
Tuesday, March 7, 2023
Pleural cavity, Radiofrequency ablation, Lung cancer, Neoplasm, Mouse, Therapy, Patient, RFA, NSCLC, Food, Society, Immune system, Investment, Immunotherapy, SIR, PEF, Food and Drug Administration, Society of Interventional Radiology, Safety, Interventional radiology, Galvanization, Trial of the century, Food preservation, Medical imaging, PHOENIX

PHOENIX, March 7, 2023 /PRNewswire/ -- New interventional oncology data from Galvanize Therapeutics demonstrate positive pre-clinical and early clinical study results using the Aliya™ Pulsed Electric Field (PEF) system.

Key Points: 
  • PEF treatment significantly reduced malignant tissue, and 95% of the assessed sensitive structures within the PEF treatment zone remained viable and unaffected by the PEF energy.
  • Additionally, PEF increased tertiary lymphoid structure accumulation, indicating potential immunoactivation with PEF.
  • PEF also showed greater suppression of tumor growth and had a synergistic effect in combination with immunotherapy, unlike RFA.
  • "We are making additional investments to expand our Aliya™ clinical research program, including a U.S. clinical study of patients with NSCLC."

Global Pleural Effusion Market Report to 2027 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022
Health, Other Health, Gaps, COVID-19, Key (company), Pleural effusion, Competitive landscape, Row, USD, Lists of people executed in the United States, SME, CAGR, Retail, Instrumentation, Marketing, Management, Pleural cavity

This report delivers an in-depth understanding of Pleural effusion and the historical and forecasted Pleural effusion market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Key Points: 
  • This report delivers an in-depth understanding of Pleural effusion and the historical and forecasted Pleural effusion market trends, globally, which comprises of North America, Europe, APAC, and RoW.
  • The Pleural effusion market report provides an overview of Pleural effusion , applications of Pleural effusion as well as its advantages and limitations.
  • Additionally the PORTER's analysis will also be provided to give an analytical edge to the Pleural effusion market report.
  • The report helps in developing business strategies by understanding trends shaping and driving the global Pleural effusion market.

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof-of-Concept for LOCOcyte™ Platform Technology in Malignant Mesothelioma

Retrieved on: 
Monday, August 22, 2022
Neoplasm, Clinical Cancer Research, Peritoneum, Mesothelioma, Investigational New Drug, The Company, Thorax, Technology, Safety, Division, Survival, Malignancy, Tumor microenvironment, View, Rice University, Pleural cavity, Platinum, Toxicity, Cardiothoracic surgery, Food and Drug Administration, Abdomen, Mouse, Pulmonary toxicity, IL2, Food, LinkedIn, Treatment of lung cancer, Lung, Multimedia, Baylor College of Medicine, PD-1, Manuscript, Baylor University, Biotechnology, FDA, Immune system, Immunotherapy, Assistant, Cancer, Twitter, Ovarian cancer, Patient, Vaccine, Pharmaceutical industry

Malignant mesothelioma and lung cancers which have metastasized to the pleural cavity remain particularly deadly with median survival times of less than a one year.

Key Points: 
  • Malignant mesothelioma and lung cancers which have metastasized to the pleural cavity remain particularly deadly with median survival times of less than a one year.
  • Mesothelioma affects the organs that are lined by the mesothelium including the organs of the chest (pleura) and abdomen (peritoneum).
  • Despite recent advances in therapies to treat malignant mesothelioma, optimal and safe delivery remains a challenge.
  • Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyteplatform.